Long-term analysis of quality of life in glioma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to conduct a large-scale, prospective analysis of health-related quality of life (HRQOL) in patients diagnosed with glioma, a common type of brain tumor. It will establish a comprehensive database that includes patient characteristics, tumor information, treatment strategies, and follow-up data. The HRQOL will be assessed using the EQ-5D questionnaire, which evaluates various health dimensions such as mobility, self-care, and psychological well-being. The study will track HRQOL over time, focusing on both low-grade and high-grade glioma patients.

Why it matters

Who can join: the full rules

Inclusion criteria:

* age ≥ 18 years
* patients diagnosed and treated for a high- or low grade glioma
* treatment in UZ Leuven

Where it's running

• UZ Leuven
  Leuven, Vlaams-Brabant, Belgium Recruiting

Study contacts

• Principal investigator: Steven De Vleeschouwer, MD Phd — UZ Leuven
• Study coordinator: Steven De Vleeschouwer, MD Phd
• Email: steven.devleeschouwer@uzleuven.be
• Phone: +3216344290

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient experiences during treatment for IDH‑mutant grade 2 gliomas: vorasidenib, radiotherapy, or observation

  This project will test how adults with IDH‑mutant grade 2 gliomas feel—their quality of life, treatment symptoms, and anxiety—when they receive vorasidenib, radiotherapy, or active surveillance.

  Recruiting Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Milan · NCT07547163

• Using Escitalopram to Improve Cognition in Glioma Patients

  This study is testing if the medication escitalopram can help improve thinking skills and mood in patients with grade IV glioma over 17 weeks.

  Recruiting Phase 2 University of Nebraska · Omaha, Nebraska · NCT03728673

• Combining capecitabine and temozolomide for newly diagnosed glioblastoma

  This study is testing if combining two cancer drugs, capecitabine and temozolomide, can help people with newly diagnosed glioblastoma live longer and feel better compared to using temozolomide alone.

  Recruiting Phase 1/2 Northwell Health · New York, New York · NCT03213002

• Laser thermal therapy for young people with low-grade glioma

  This research will test whether laser interstitial thermal therapy (LITT) can stop or slow recurrent or progressive low-grade gliomas in children, adolescents, and young adults.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07506239

• Dabrafenib and trametinib dose-reduction for BRAF V600 low-grade glioma

  This trial tries to see if stopping or slowly lowering dabrafenib and trametinib after about 12–24 months works for people with BRAF V600–mutant low-grade glioma.

  Recruiting at 12 sites Phase 2 University of California, San Francisco · Birmingham, Alabama and 11 other locations · NCT07110246

• Vorasidenib plus tumor-specific peptide vaccine for recurrent IDH1-mutant lower-grade glioma

  This will test whether combining the oral drug vorasidenib with a tumor-specific peptide vaccine helps adults with recurrent IDH1-mutant lower-grade glioma.

  Recruiting Phase 1 Duke University · Durham, North Carolina · NCT05609994

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.